Breaking News

Cytovance Expands Gene Therapy Service Capabilities

Introduces an integrated single-use platform for plasmid DNA manufacture at Oklahoma facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cytovance Biologics has introduced an integrated single-use platform for the manufacturing of plasmid DNA (pDNA) at their facilities in Oklahoma City, OK. Two grades are available (Critical Reagent Grade, CGMP-grade) in lot sizes from 1g to 50g. One grade is available (R&D-grade) in lot sizes from 1g to 5g.   With the increasing market growth and demand for pDNA, specifically the gene therapy market, Cytovance Biologics’ addition of this integrated platform will enhance its overall offering ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters